Search Patents
-
Patent number: 7129042Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.Type: GrantFiled: November 3, 2003Date of Patent: October 31, 2006Assignees: Diagnostic Hybrids, Inc., Health Research IncorporatedInventors: Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick
-
Patent number: 11512115Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.Type: GrantFiled: May 6, 2020Date of Patent: November 29, 2022Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
-
Patent number: 7452542Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.Type: GrantFiled: May 23, 2005Date of Patent: November 18, 2008Assignee: Vanderbilt UniversityInventor: Mark Denison
-
Publication number: 20150050308Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.Type: ApplicationFiled: August 13, 2014Publication date: February 19, 2015Inventor: Cornelia Maria van der Hoek
-
Publication number: 20120082693Abstract: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine.Type: ApplicationFiled: July 20, 2011Publication date: April 5, 2012Inventors: Sylvie VAN DER WERF, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Publication number: 20040175829Abstract: The present invention shows that expressed coronavirus envelope protein M specifically interacted with co-expressed non-coronavirus RNA transcripts containing the short viral packaging signal in the absence of coronavirus N protein. Furthermore, this M protein-packaging signal interaction led to specific packaging of the packaging-signal-containing RNA transcripts into coronavirus-like particles in the absence of N protein. These findings highlight a novel RNA packaging mechanism for an enveloped virus, and a novel coronavirus-based expression system can be developed based on the data presented herein.Type: ApplicationFiled: March 5, 2004Publication date: September 9, 2004Inventors: Shinji Makino, Krishna Narayanan
-
Publication number: 20110065089Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.Type: ApplicationFiled: April 6, 2010Publication date: March 17, 2011Inventors: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Publication number: 20040235132Abstract: A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon.Type: ApplicationFiled: May 25, 2004Publication date: November 25, 2004Inventors: Kristopher M. Curtis, Boyd Yount, Ralph S. Baric
-
Patent number: 7220852Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.Type: GrantFiled: April 12, 2004Date of Patent: May 22, 2007Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Suxiang Tong, Sherif R. Zaki
-
Publication number: 20120177675Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.Type: ApplicationFiled: July 5, 2010Publication date: July 12, 2012Applicant: INSTITUTE FOR ANIMAL HEALTHInventors: Paul Britton, Erica Bickerton, Maria Armesto
-
Patent number: 7618802Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.Type: GrantFiled: January 19, 2006Date of Patent: November 17, 2009Assignee: The University of North Carolina at Chapel HillInventors: Ralph S. Baric, Rhonda Roberts, Boyd Yount, Kristopher M. Curtis
-
Patent number: 8828407Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.Type: GrantFiled: July 5, 2010Date of Patent: September 9, 2014Assignee: The Pirbright InstituteInventors: Paul Britton, Erica Bickerton, Maria Armesto
-
Publication number: 20090214587Abstract: The present invention provides a recombinant virus which is efficacious and highly safe in preventing the onset of SARS infection and a vaccine for SARS coronavirus containing the same. The recombinant virus of the invention can express a SARS coronavirus gene.Type: ApplicationFiled: October 11, 2005Publication date: August 27, 2009Applicants: Post Genome Institute Co., Ltd., The Chemo-Sero-Therapeutic Research InstituteInventors: Michinori Kohara, Kyosuke Mizuno, Hisatoshi Shida, Kouji Matsushima, Koichi Morita, Minoru Kidokoro, Yukie Sameshima
-
Patent number: 7482149Abstract: The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN ?-n1, IFN ?-n3, human leukocyte IFN ? or IFN ?-1b.Type: GrantFiled: June 9, 2004Date of Patent: January 27, 2009Assignee: Genome Institute of SingaporeInventors: Emily Li Chuan Tan, Lawrence W. Stanton
-
Publication number: 20040038202Abstract: The present invention relates to the use of novel nucleotide sequences for the spike peptide, pol region peptide and M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.Type: ApplicationFiled: January 30, 2003Publication date: February 26, 2004Applicant: Michigan State UniversityInventors: Roger K. Maes, Annabel G. Wise, Matti Kiupel
-
Publication number: 20080206283Abstract: The present invention provides nucleotide sequences from SARS (Serve Acute Respiratory Syndrome) coronavirus genomes, as well as the applications of the partial fragments thereof in preparing DNA vaccine or expressing corresponding proteins. Furthermore, the present invention also provides the uses of said proteins in preventing and treating diseases, and preparing antibodies.Type: ApplicationFiled: June 17, 2004Publication date: August 28, 2008Inventors: Xiangjun Zhou, John Y. Dong
-
Publication number: 20130071833Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.Type: ApplicationFiled: January 18, 2011Publication date: March 21, 2013Applicant: Universiteit Utrecht Holding B.V.Inventors: Petrus Josephus Marie Rottier, Hui-Wen Chang, Herman F. Egberink
-
Patent number: 7897744Abstract: The invention provides, in part, the genomic sequence of a putative coronavirus, the SARS virus, and provides novel nucleic acid and amino acid sequences that may be used, for example, for the diagnosis, prophylaxis, or therapy of a variety of SARS virus related disorders.Type: GrantFiled: April 28, 2004Date of Patent: March 1, 2011Assignee: The Public Health Agency of CanadaInventors: Frank Plummer, Heinz Feldmann, Steven Jones, Yan Li, Nathalie Bastien, Robert Conrad Brunham, Angela Brooks-Wilson, Robert Holt, Christopher Upton, Rachel Roper, Caroline Astell, Steven Jones
-
Patent number: 11119103Abstract: Provided herein is a test system comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen, SARS-CoV-2 S2 antigen, and binding moieties that specifically bind to human IgG, human IgA, and human IgM. Also provided are methods of detecting SARS-CoV-2 antibodies in a sample using the test system.Type: GrantFiled: June 12, 2020Date of Patent: September 14, 2021Assignee: Arizona Board of Regents on Behalf of the University of Arizona, a body corporateInventors: Deepta Bhattacharya, Ryan Sprissler, Janko Nikolich-Zugich, Matthew Kaplan, Tyler Ripperger, Jennifer Uhrlaub, Makiko Watanabe, Rachel Wong
-
Publication number: 20080069839Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.Type: ApplicationFiled: May 24, 2004Publication date: March 20, 2008Inventors: Yi Guan, Bo-Jiang Zheng